Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why GlaxoSmithKline plc (ADR) (GSK) Will Survive the China Scandal

Page 1 of 2

GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of the violation of Chinese laws wherein the company’s key officials have used around 700 agencies and firms for increasing the sales and prices of drugs by bribing hospitals and doctors in China. The company has transferred around $489 million to these agencies. Four of the company’s executives are detained. This includes the vice president, the legal affairs director, the business development manager and the human resource director.

GlaxoSmithKline plc (ADR) (NYSE:GSK)However, this should not be much of a concern as the company is in continuous process to rectify its fault and cut down the prices. Also, this is more of an inborn problem of China, rather than the company itself. It is the management of Chinese hospitals and the government who are responsible for such a shameful event.

Low prices for hospital services, as enforced by government, leaves no option but to keep the price of drugs high to make a profit. Instances such as these make it clear that it is not the drug making company, but individuals involved in the process that are responsible, and this should not have any long term effect on the functioning of the company.

Let us have a look at some of the key points that will help GlaxoSmithKline plc (ADR) (NYSE:GSK) come out of this short term problem.

Strong fundamentals

Half yearly results for 2013 have shown an increase in EBITDA by 13% to £3997 million. EBITDA margin for the period increased by 400 basis points to 31% compared to the first half of 2012, indicating increased operating efficiency. Operating and free cash flows have been positive in the past five years. The debt component in the capital structure is higher than its peers. Yet a high interest coverage ratio of 72 indicates that the company has managed its debt very efficiently and is generating enough revenue to meet its debt obligation. Investment returns are also very high with ROE and ROA being 54.5% and 10.1%, respectively, as compared to the industry average of 11.2% and 5.7%, respectively.

Interest Coverage Leverage D/E Current ratio ROE ROA
GSK 72 6.4 2.6 1.2 54.5 10.1
JNJ 14.5 1.8 0.2 2.1 16.3 8.8
MRK 23.3 2 0.3 2 11.2 5.7
Industry average 28.4 2.3 0.4 1.7 19.4 8.8

Page 1 of 2
Loading Comments...